Structure Therapeutics
GPCR
197 hedge funds and large institutions have $4.58B invested in Structure Therapeutics in 2025 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 52 increasing their positions, 62 reducing their positions, and 27 closing their positions.
433% more funds holding in top 10
Funds holding in top 10: 3 → 16 (+13)
243% more call options, than puts
Call options by funds: $62.6M | Put options by funds: $18.2M
189% more capital invested
Capital invested by funds: $1.58B → $4.58B (+$3B)
163% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 27
26% more funds holding
Funds holding: 156 → 197 (+41)
10.07% more ownership
Funds ownership: 98.33% → 108.4% (+10%)
16% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$141M |
| 2 |
Morgan Stanley
New York
|
+$61.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$58.5M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$57.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$56.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$45.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$42.5M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$38.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$18M |
| 5 |
CCM
Catalio Capital Management
New York
|
-$16.3M |
GPCR Hedge Fund Activity: Q4 2025 in Review
197 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q4 2025, worth a combined $4.58B — up 189% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new GPCR positions and 27 closed out — a net gain of 44 holders — while 52 added to existing stakes and 62 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $141M. The largest seller was Millennium Management, cutting an estimated $45.8M.
- 197 institutional investors held Structure Therapeutics (GPCR) as of Q4 2025, up from 156 in Q3 2025.
- Funds reported $4.58B of Structure Therapeutics stock for Q4 2025, up 189% quarter-over-quarter.
- 71 funds opened new Structure Therapeutics positions in Q4 2025 and 27 closed out, a net change of +44 holders.
- The largest Structure Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $141M added.
- The largest Structure Therapeutics seller in Q4 2025 was Millennium Management, an estimated $45.8M sold.
Based on aggregated 13F filings for Q4 2025.